AstraZeneca expanding its leadership in biopharmaceutical research [Video]

In January, AstraZeneca announced an $820 million investment in Canada. This latest commitment creates more than 700 highly skilled jobs across all areas of the business. This news follows a $500M investment in 2023, as well as AstraZeneca’s 2024 acquisition of Hamilton-based Fusion Pharmaceuticals Inc. for $3 billion in one of the largest research investments ever made in a Canadian biotechnology company.

“It’s an incredibly exciting time for AstraZeneca in Canada,” says Gaby Bourbara, President, AstraZeneca Canada. “Since 2023, we have invested $4.3 billion in Canada’s life sciences sector. We have created more than 1,200 highly skilled jobs that are helping us develop and deliver life-changing medicines. With our acquisition of Fusion Pharmaceuticals Inc., we are supporting innovative research that could redefine radiotherapy for cancer patients.”

These investments have also included the expansion of AstraZeneca’s Global Research and Development (R&D) Hub and the creation of a new Alexion R&D Hub …